Over 140 rare cannabinoids exist in the cannabis plant – some with the potential to have more therapeutic benefits than those cannabinoids found prominently in the plant InMed and subsidiary BayMedica plan to release several rare cannabinoid products in the … Continue reading →

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. According to the piece, InMed achieved Q222 financial … Continue reading →

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his … Continue reading →

InMed Pharmaceuticals (NASDAQ: INM) understands the immense potential of rare cannabinoids and sees them as having applications as wide as cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), variants of cannabinoids that make up most of the content in cannabis plants. Studies suggest … Continue reading →

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced that it will report its second-quarter financial results next week on Feb. 15, 2022; the results will cover the period ending Dec. 31, … Continue reading →

Cannabicitran is the first of four new rare cannabinoids InMed is planning to launch in the first half of the year to meet growing inbound demand The launch demonstrates InMed’s ability to produce rare cannabinoids at scale, something only very … Continue reading →

InMed Pharmaceuticals (NASDAQ: INM) is a trailblazer, a pioneer defining the value of rare cannabinoids in the pharmaceutical sector and just how integral they are in pushing the industry forward. The global cannabis market is experiencing tremendous growth, particularly considering … Continue reading →

Rare cannabinoids are cannabinoid compounds other than CBD and THC which are not yet produced in large scale but which have potentially greater benefits InMed acquired BayMedica in October 2021, bringing on board unmatched expertise in large-scale bio-production technologies applicable … Continue reading →

The global cannabinoid-based pharmaceuticals market is projected to be valued at $50 billion by 2029 InMed is leading the industry, laying down the foundation in manufacturing and clinical development of rare cannabinoids It is shedding light on the potential of … Continue reading →

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it has launched B2B sales of the rare cannabinoid cannabicitran (“CBT”) into the health and wellness sector. According to the update, … Continue reading →